Goldman Sachs
HRTX icon

Goldman Sachs’s Heron Therapeutics HRTX Stock Holding History

Goldman Sachs’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-155,000
Closed -$2.88M – 5255
2019
Q2 		$2.88M Buy
+155,000
New +$3.1M ﹤0.01% 3269
2018
Q1 		– Sell
-1,700
Closed -$31K – 6108
2017
Q4 		$31K Buy
1,700
+1,100
+183% +$17.9K ﹤0.01% 6038
2017
Q3 		$10K Buy
+600
New +$9.41K ﹤0.01% 6531
2017
Q2 		– Sell
-1,400
Closed -$21K – 6842
2017
Q1 		$21K Buy
+1,400
New +$19.4K ﹤0.01% 6500
2016
Q4 		– Sell
-100
Closed -$2K – 6970
2016
Q3 		$2K Sell
100
-6,500
-98% -$121K ﹤0.01% 6965
2016
Q2 		$119K Sell
6,600
-43,400
-87% -$847K ﹤0.01% 6035
2016
Q1 		$950K Buy
50,000
+47,500
+1,900% +$937K ﹤0.01% 4114
2015
Q4 		$67K Sell
2,500
-499,300
-100% -$13.4M ﹤0.01% 6401
2015
Q3 		$12.2M Buy
+501,800
New +$16.7M ﹤0.01% 2097

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

Goldman Sachs's HRTX Position: Q1 2026 in Review

Goldman Sachs increased its Heron Therapeutics (HRTX) stake by 6.8% in Q1 2026, buying an estimated $77.8K and bringing the position to 1,056,944 shares worth $846K. The position accounts for ﹤0.01% of the portfolio, ranked #5219.

Goldman Sachs first reported a position in HRTX in Q1 2014 and has held it in 46 quarters since. The position peaked at $36.1M in Q4 2019. 167 funds tracked by Wall St. Rank hold HRTX as of Q1 2026.

  • Goldman Sachs held 1,056,944 shares of Heron Therapeutics worth $846K as of Q1 2026.
  • Goldman Sachs bought 67,148 Heron Therapeutics shares in Q1 2026, an estimated $77.8K.
  • Heron Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #5219 holding.
  • Goldman Sachs first reported a position in Heron Therapeutics in Q1 2014 and has held it in 46 quarters since.
  • Goldman Sachs's Heron Therapeutics position peaked at $36.1M in Q4 2019.
  • 167 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.